波音游戏-波音娱乐城赌球打不开

HUANG, Yu

HUANG, Yu (黃聿)

Head

Chair Professor of Biomedical Sciences and Vascular Biology

Jeanie Hu Professorship in Biomedical Sciences

MPhil & PhD (University of Cambridge)

BSc (Fudan University Shanghai Medical School)

  • 1A-108, 1/F, Block 1, To Yuen Building
  • +852 3442-7746
  • +852 3442-0549
  • CityU Scholars
  • Lab Website
  • Vascular and Metabolic Biology • Atherosclerosis • Mechanobiology • Exercise and Health Benefits

Yu HUANG is Jeanie Hu Professor of Biomedical Sciences and Chair Professor of Biomedical Sciences and Vascular Biology at City University of Hong Kong, where he leads the Department of Biomedical Sciences. He received a BSc degree from Fudan University Shanghai Medical College and a PhD from the University of Cambridge. Prior to joining CityU in 2021, he was a A3 Professor of Biomedical Sciences at Chinese University of Hong Kong and the founding Director (Basic Sciences) of the Heart and Vascular Institute.

The aim of Huang’s team is to investigate the cellular and molecular processes that cause endothelial cell dysfunction in high blood pressure, obesity and diabetes. They also aim to find new biomarkers for vascular disease and to discover ways to reverse vascular dysfunction in animal models of cardio-metabolic disorders. He has co-authored 509 publications in SCI-indexed journals including Nature, Science, Cell Metabolism, Circulation Research, European Heart Journal, PNAS, Diabetes, Hypertension, ATVB, Stroke, Kidney International, etc. His work has earned him over 35,450 citations on Google Scholar (an h-index of 97). He is one of the Stanford’s list of world’s top 2% most highly cited scientists, both career-long and single year for 2020, 2021, 2022, 2023 (318/94,611 top 0.3% in Pharmacology & Pharmacy for 2020; 273/131,949 top 0.2% in Pharmacology & Pharmacy for 2021; 318/134,745 top 0.2% in Pharmacology & Pharmacy for 2022; 1,505/210,400 top 0.7% in Cardiovascular System & Hematology for 2023).

黃聿是香港城市大學(xué)生物醫(yī)學(xué)胡梁子慧生物醫(yī)學(xué)教授、生物醫(yī)學(xué)和血管生物學(xué)講座教授、生物醫(yī)學(xué)系系主任。他於復(fù)旦大學(xué)上海醫(yī)學(xué)院獲得學(xué)士學(xué)位,並於劍橋大學(xué)獲得博士學(xué)位。在2021年加入香港城市大學(xué)之前,他是香港中文大學(xué)生物醫(yī)學(xué)A3級(jí)講座教授,也是心血管研究所的創(chuàng)始所長(zhǎng) (基礎(chǔ)科學(xué))。

黃聿教授曾擔(dān)任亞洲血管生物學(xué)會(huì)主席 (2010–2018) 和中國(guó)血管醫(yī)學(xué)專業(yè)委員會(huì)副主任委員 (2015–2021)。目前,他是中國(guó)生理學(xué)會(huì)副理事長(zhǎng) (2022–) 和國(guó)際心臟研究學(xué)會(huì)中國(guó)分會(huì)副主席 (2016–)。黃聿教授於2019年被選為國(guó)際心臟研究學(xué)會(huì)Fellow,於2020年獲得首屆香港研究資助局高級(jí)研究員獎(jiǎng),2023年被推選為國(guó)際生理科學(xué)聯(lián)合會(huì)生理學(xué)院Fellow以及英國(guó)藥理學(xué)會(huì)Fellow。他還是心血管疾病國(guó)家重點(diǎn)實(shí)驗(yàn)室學(xué)術(shù)委員會(huì)委員和中國(guó)國(guó)家心血管專家委員會(huì)委員。

黃教授擔(dān)任多個(gè)基金組織的評(píng)審小組成員,包括香港研究資助局、香港醫(yī)療衛(wèi)生研究基金、中國(guó)自然科學(xué)基金委員會(huì)、香港創(chuàng)新及科技基金,也是澳門大學(xué)生物醫(yī)學(xué)科學(xué)評(píng)審小組主席。他曾先後在18個(gè)SCI學(xué)術(shù)期刊擔(dān)任編輯、客座編輯、副主編和編委,包括循環(huán)研究副主編。此外,他評(píng)審過(guò)15個(gè)國(guó)家和地區(qū)的36個(gè)研究資助機(jī)構(gòu)的基金申請(qǐng)標(biāo)書。黃教授先後被12所大學(xué)和研究所聘為客座教授,其中包括復(fù)旦大學(xué)上海醫(yī)學(xué)院、中國(guó)科學(xué)技術(shù)大學(xué)、澳門大學(xué)、馬來(lái)亞大學(xué)、上海交通大學(xué)醫(yī)學(xué)院、北京大學(xué)基礎(chǔ)醫(yī)學(xué)院、西安交通大學(xué)醫(yī)學(xué)院。

黃教授團(tuán)隊(duì)的研究聚焦於高血壓、肥胖和糖尿病等疾病中引發(fā)內(nèi)皮細(xì)胞功能障的細(xì)胞和分子生物學(xué)過(guò)程,旨在發(fā)現(xiàn)血管發(fā)病機(jī)制的新型生物標(biāo)記物,從而在血管-代謝紊亂疾病動(dòng)物模型中開發(fā)能夠逆轉(zhuǎn)血管功能障礙的新途徑。他已發(fā)表509篇SCI論文,論文發(fā)表雜誌包括Nature、Science、Cell Metabolism、Circulation Research、European Heart Journal、PNAS、Diabetes、Hypertension、ATVB、Stroke,總被引用超過(guò)35,450次,H-指數(shù)是97 (Google Scholar Citation)。

黃聿教授曾榮獲由國(guó)際心臟研究學(xué)會(huì)頒發(fā)的2024年度Peter Harris傑出科學(xué)家獎(jiǎng)、中國(guó)病理生理學(xué)會(huì)血管醫(yī)學(xué)專業(yè)委員會(huì)傑出貢獻(xiàn)獎(jiǎng) (2021)、2020年度藥明康德生命化學(xué)研究獎(jiǎng)、由國(guó)家教育部頒發(fā)的高等學(xué)校科學(xué)研究?jī)?yōu)秀成果獎(jiǎng) (2019年度自然科學(xué)獎(jiǎng)一等獎(jiǎng)、2012和2017年度自然科學(xué)獎(jiǎng)二等獎(jiǎng))、中國(guó)國(guó)家自然科學(xué)獎(jiǎng)二等獎(jiǎng) (2015)、香港裘槎基金會(huì)裘槎優(yōu)秀科學(xué)研究者獎(jiǎng) (2014)。

他擔(dān)任主講嘉賓,受邀在貝時(shí)璋講座 (中國(guó)科學(xué)技術(shù)大學(xué),2023)、第十九屆世界基礎(chǔ)與臨床藥理學(xué)大會(huì)主題演講 (WCP2023,格拉斯哥,蘇格蘭)、亞洲血管生物學(xué)講座 (亞洲血管生物學(xué)大會(huì),上海,2018)、The Robert F. Furchgott 講座 (蘇黎世,2013) 和新加坡國(guó)立大學(xué)傑出學(xué)人講座 (2007)。

更多資訊:https://www.cuhk.edu.hk/proj/HuangLab/profile.html

Since joining CityU in October 2021, Prof. Huang has secured one Theme-based Research Scheme (2023–2024), three GRFs (2022, 2023, 2024) and one HMRF (2022) as PC/PI totalling HKD 61,543,935, and HKD 3,200,000 allocation from another Theme-based Research Scheme (2022–2023) as Co-PI.

As PC/PI (>100M HK dollars) and as Co-PI with actual allocation (>16.8M HK dollars) from RGC:

  • 1 RGC – Theme-based Research Scheme as PC (2023)
  • 1 Inaugural Hong Kong Research Grants Council (RGC) Senior Research Fellow Scheme (2021)
  • 1 Hong Kong Croucher Senior Research Fellowship (2014)
  • 2 RGC – Collaborative Research Fund as PC (2013, 2016)
  • 19 Earmarked RGC and RGC-General Research Fund grants since 1995 as PI
  • 1 Natural Science Foundation of China, Major Research Program on Vascular Homeostasis and Remodelling (國(guó)家自然科學(xué)基金重大研究計(jì)畫項(xiàng)目) as PI (2019)
  • 1 NSFC/RGC Joint Research Scheme as PI (2009)
  • 8 Health and Medical Research Fund, Food and Health Bureau, Hong Kong SAR, as PI (2013, 2015, 2016, 2017, 2018, 2019, 2020, 2021)
  • 1 Health Grant from Food and Health Bureau as PI (2009)
  • 1 NSFC Grant on Major Research Scheme on Vascular Homeostasis as PI (2012)
  • 1 NSFC – Australia Joint Research Scheme on Diabetes as PI (2016)
  • 13 RGC – funded Joint Research Scheme (International Collaborative Grants) as Hong Kong Coordinator
  • 1 Innovation and Technology Fund, HK as PI (2023)
  • 3 RGC – Theme-based Research Scheme (Co-investigator, 2012; Co-PI, 2014; Co-PI, 2022)
  • 1 RGC – Areas of Excellence Scheme (Co-PI, 2019)
  • 1 RGC – Research Impact Fund (Co-PI, 2019)
  • 5 RGC Collaborative Research Fund (CRF) as Co-PI (2007, 2008, 2011, 2015, 2018)

  • Elected Fellow, British Pharmacological Society (October 2023)
  • Elected Fellow, Academy of Physiology, International Union of Physiological Sciences (April 2023)
  • Elected Fellow, the International Society of Heart Research (ishr, 2019)
  • Inaugural Hong Kong Research Grants Council (RGC) Senior Research Fellow Award (2020–2021年度首屆香港研究資助局高級(jí)研究學(xué)者獎(jiǎng))
  • Croucher Senior Research Fellowship Award (2014), Hong Kong Croucher Foundation (裘槎優(yōu)秀科研者獎(jiǎng), 2014, 香港裘槎基金會(huì))

  • 2024 Peter Harris Distinguished Scientist Award of the International Society for Heart Research (April 2024)
  • Outstanding Contribution Award, Chinese Society for Vascular Medicine, Chinese Association of Pathophysiology (中國(guó)病理生理學(xué)會(huì)血管醫(yī)學(xué)專業(yè)委員會(huì)傑出貢獻(xiàn)獎(jiǎng), July 2021)
  • 2020 Wuxi PharmaTech Life Science and Chemistry Award – The Scholar Award (2020年度藥明康德生命化學(xué)研究獎(jiǎng)學(xué)者獎(jiǎng))
  • 2019 Higher Education Outstanding Scientific Research Output Award (first-class award), Ministry of Education, People Republic of China (2019年度高等學(xué)校科學(xué)研究?jī)?yōu)秀成果獎(jiǎng) – 自然科學(xué)一等獎(jiǎng))
  • 2017 Higher Education Outstanding Scientific Research Output Award (second-class award), Ministry of Education, People Republic of China (2017年度高等學(xué)校科學(xué)研究?jī)?yōu)秀成果獎(jiǎng) – 自然科學(xué)二等獎(jiǎng), 2018)
  • Research Excellence Award 2016–2017, Chinese University of Hong Kong (香港中文大學(xué)研究卓越獎(jiǎng), 2017)
  • Second-class Award, The State Natural Science Award, China (中國(guó)國(guó)家自然科學(xué)獎(jiǎng)二等獎(jiǎng), 2015)
  • First-class Award, The Natural Science Award, Chongqing Municipality Government (中國(guó)重慶市科學(xué)技術(shù)獎(jiǎng) – 自然科學(xué)獎(jiǎng)一等獎(jiǎng), April 2013)
  • Research Excellence Award 2011–2012, Chinese University of Hong Kong (香港中文大學(xué)研究卓越獎(jiǎng), 2012)
  • 2011 Higher Education Outstanding Scientific Research Output Award (second-class award), Ministry of Education, People Republic of China (2011年度高等學(xué)校科學(xué)研究?jī)?yōu)秀成果獎(jiǎng) – 自然科學(xué)二等獎(jiǎng), 2012)
  • The Postgraduate Research Output Award 2011, The Chinese University of Hong Kong (Mentor of the awardee, Xiaoyu Tian)
  • The Postgraduate Research Output Award 2009, The Chinese University of Hong Kong (Mentor of the awardee, Siu Ling Wong)
  • Jeanie Hu Professor in Biomedical Sciences, City University of Hong Kong (July 2022–)
  • UM Macao Distinguished Visiting Scholar, University of Macau (2019)
  • Visiting Professorship under Academic Icon Program, University of Malaya (2012–2016)

  • Member of Biology Panel for Research Assessment Exercise 2026, The University Grants Committee (UGC) of Hong Kong (2024)
  • Member of the Biology and Medicine Panel of the Research Grants Council, Hong Kong (December 2017 – 2023)
  • Member of the Grant Review Board, Health and Medical Research Fund, Food and Health Bureau, Hong Kong SAR Government (2013–)
  • Member of Innovation and Technology Fund (ITF), Hong Kong Government’s Innovation and Technology Commission (2023–)
  • Member of Review Panel of Major Research Program on Regulation of Vascular Homeostasis and Remodeling, Natural Science Foundation of China (2014–)
  • Panel Member of University of Macau Multi-Year Research Grant in Engineering and Science, University of Macau (2013–2020)
  • Chair of the Panel on Biomedical Sciences, the Multi-Year Research Grant, University of Macau (2021–)
  • Member of the Academic Committee of the Hong Kong Scholar Program, Hong Kong Special Administrative Region (香江學(xué)者計(jì)劃, 2011–)

  • Vice-President, Chinese Association for Physiological Sciences (中國(guó)生理學(xué)會(huì)副理事長(zhǎng), November 2022)
  • Vice-President, The Chinese Section, International Society of Heart Research (國(guó)際心臟研究會(huì)中國(guó)分會(huì)副主席, 2016–)
  • Vice Chairman of Academic Committee for The Key Laboratory of Geriatric Cardiovascular and Cerebrovascular Disease Research, Ministry of Education of China (老年心腦血管病教育部重點(diǎn)實(shí)驗(yàn)室學(xué)術(shù)委員會(huì)副主任, January 2024)
  • Vice Chairman of Academic Committee for Institute of Endocrine and Metabolic Disease, University of Science and Technology of China and Anhui Provincial Key Laboratory of Metabolic Health and Panvascular Diseases (中國(guó)科學(xué)技術(shù)大學(xué)內(nèi)分泌與代謝病研究所, 代謝建康與渙血管病安徽省重點(diǎn)實(shí)驗(yàn)室學(xué)術(shù)委員會(huì)副主任, August 2023)
  • Vice-President, Society of Vascular Medicine, Chinese Association of Pathophysiology (中國(guó)病理生理學(xué)會(huì)心血醫(yī)學(xué)專業(yè)委員會(huì)副主任委員, 2015–2021)
  • President, Asian Society for Vascular Biology (2010–2018)
  • Secretary-General and the founding member of the Asian Society for Vascular Biology (2005–2010)
  • Council Member, the Asian Society for Vascular Biology (2018–)
  • Elected voting member (representing Asia) of the five-member Membership Committee, the International Union of Basic and Clinical Pharmacology (2006–2018)
  • Corresponding member of the International Union of Basic and Clinical Pharmacology (IUPHAR) Committee on Receptor Nomenclature and Drug Classification (2011–)
  • Member of the Scientific Committee, State Key Laboratory of Cardiovascular Disease (心血管疾病國(guó)家重點(diǎn)實(shí)驗(yàn)室學(xué)術(shù)委員會(huì)委員, April 2022–)
  • Member of the Committee of Experts on National Center for Cardiovascular Diseases (中國(guó)國(guó)家心血管專家委員會(huì)第二屆委員會(huì)委員, September 2019–)
  • Executive Council Member, Cardiovascular Immunology Sub-Committee, Chinese Society for Immunology (中國(guó)免疫學(xué)會(huì)心血管免疫分會(huì)常務(wù)理事, June 2024 – 2028)
  • Elected Executive Council Member of the Chinese Association for Physiological Sciences (中國(guó)生理學(xué)會(huì)常務(wù)理事, November 2022–)
  • Council Member, The Chinese Association of Pathophysiology (中國(guó)病理生理學(xué)會(huì)理事, 2010–)
  • Elected Council Member, The Chinese Society of Cardiovascular Pathophysiology (中國(guó)病理生理學(xué)會(huì)心血管專業(yè)委員會(huì)理事, 2008–)
  • Council Member, Society of Vascular Medicine, Chinese Association of Pathophysiology (中國(guó)病理生理學(xué)會(huì)心血醫(yī)學(xué)專業(yè)委員會(huì)理事, 2015–)
  • Council Member of the Chinese Section, the International Society of Heart Research (國(guó)際心臟研究會(huì)中國(guó)分會(huì)理事, 2008–)
  • Council Member of The International Society for Heart Research – Chinese Committee of Translational Medicine (ISHR-CCTM, 2014–2016)
  • Executive Council Member of The International Society for Heart Research – Chinese Committee of Translational Medicine (ISHR-CCTM, 國(guó)際心臟研究會(huì)中國(guó)轉(zhuǎn)化醫(yī)學(xué)工作委員會(huì)常務(wù)理事, 2016–)
  • Executive Council Member, The Chinese Society of Cardiovascular Pharmacology (中國(guó)藥理學(xué)會(huì)心血管專業(yè)委員會(huì)常務(wù)理事, 2007–)
  • Elected Council Member, The Chinese Society of Circulatory Physiology, Chinese Association for Physiological Sciences (中國(guó)生理學(xué)會(huì)循環(huán)生理專業(yè)委員會(huì)理事, 2015–2018)
  • Executive Council Member, 2nd Board of Specialty Committee of TCM Pharmacology, World Federation of Chinese Medicine Societies (世界中醫(yī)藥學(xué)會(huì)聯(lián)合會(huì)中藥藥理專業(yè)委員會(huì)常務(wù)理事, January 2014 – 2018)
  • Member of Public Affair Committee, The Academy of Cardiovascular Research Excellence, USA (2003–)
  • 第三屆海峽兩岸醫(yī)藥衛(wèi)生交流協(xié)會(huì)心血管專業(yè)委員會(huì)常務(wù)委員 (2021–)
  • Executive Council Member (2000–2001) and Treasurer (2001–2008), Hong Kong Society of Neurosciences
  • Executive Committee Member (2003–), Honorary Secretary (2006–2008), and Treasurer (2009–2012), Hong Kong Pharmacology Society
  • Vice-President, Hong Kong Society of Cell Biology (2018–)
  • Council Member, Institute of Cardiovascular Science and Medicine, Hong Kong (2008–)
  • Deputy Director, Institute of Cardiovascular Science and Medicine, Hong Kong (2023–)
  • Secretary (Internal Affair, 2011–2013), Vice-President (External Affair, 2013–2015, 2015–2017, 2017–2020), Council Member (2021–2023) for The Society of Hong Kong Scholars

  • Associate Editor, Experimental Physiology (London, 2002 –2003)
  • Editor, Experimental Physiology (London, 2003–2006)
  • Editor (Vascular), Clinical and Experimental Pharmacology and Physiology (Australia, 2007–2012)
  • Editor, Drug Discoveries & Therapeutics (Japan, 2008–)
  • Editor, Naunyn-Schmiedeberg's Archives of Pharmacology (Europe, 2012–2019)
  • Reviewer Editor, Frontiers in Pharmacotherapy of Inflammation (Switzerland, 2010–), Frontiers in Cardiovascular and Smooth Muscle Pharmacology (Switzerland, 2010–); Frontier in Vascular Physiology (Switzerland, 2010–); Frontiers in Ethnopharmacology (Switzerland, 2013–)
  • Academic Editor, PLoS One (2011–2019, USA)
  • Associate Editor (Cardiovascular), Clinical and Experimental Pharmacology and Physiology (2014–2018)
  • Co-Guest Editor for Journal of Cardiovascular Pharmacology (USA, 2014–2015)
  • Co-Guest Editor for British Journal of Pharmacology (UK, 2016–2017)
  • Editor for British Journal of Pharmacology (UK, 2018–)
  • Associate Editor, Circulation Research (American Heart Association, USA, 2019–)
  • Co-Guest Editor for Journal of Molecular and Cellular Cardiology (USA, 2021–2022)
  • Co-Guest Editor for Antioxidants (2021–2022)
  • Member of Editorial Board or Editorial Advisory Board (past and present) for SCI-indexed journals including
    • Journal of Vascular Research, Europe (2007–2018)
    • Cardiovascular Drug & Therapy, Europe (2011–)
    • The Journal of Pharmacy and Pharmacology (UK, 2011–)
    • American Journal of Cardiovascular Disease (USA, 2011–)
    • Advanced Biomedical Research (2012)
    • Arteriosclerosis, Thrombosis and Vascular Biology (USA, 2012–)
    • Acta Pharmacologica Sinica (China, 2012–)
    • Journal of Cardiovascular Diseases & Diagnosis (USA, 2013–)
    • Clinical and Experimental Research in Cardiology (USA, 2014–)
    • World Journal of Traditional Chinese Medicine (2014–2016)
    • Scientific Reports (UK, 2014–2019)
    • Biomedical Research (2016–)
    • British Journal of Pharmacology (UK, 2018–)
    • Cardiovascular Research (Europe, 2018–)
    • Journal of Molecular and Cellular Cardiology (USA, 2018–)
  • Member of Editorial Board (past and present) for Chinese scientific journals including
    • Chinese Journal of New Drugs and Clinical Remedies (2004–)
    • Journal of Chinese Clinical Medicine (English Edition) (2006–2012)
    • Acta Physiological Sinica (2011–)
    • Journal of Physiology Studies (2013–)
    • Medical Review (2023–)

  • Keynote Lecture at the 7th Asia-Pacific CardioMetabolic Syndrome Congress (APCMS), Seoul, Korea, 26 April 2024
  • 2024 Peter Harris Distinguished Scientist Award Lecture at ISHR Chinese Section Scientific Meeting, Wuxi, China, 12 April 2024
  • Keynote Lecture at 8th International Conference on Biomedical Engineering and Applications (ICBEA 2024), Tokyo, Japan, 19 March 2024
  • Bei Shi Zhang Lecture (貝時(shí)璋講座) in University of Science and Technology of China, Anhui, China, 18 August 2023
  • Keynote Lecture at 2023 Scientific Conference of Malaysian Society of Pharmacology and Physiology, Malaysia, 7 August 2023
  • Keynote Lecture at Chinese Congress on Redox Biology and Medicine, Xiamen, 12 August 2023
  • Keynote Lecture at 19th World Congress of Basic and Clinical Pharmacology – WCP2023, Glasgow, Scotland, 4 July 2023
  • The President’s Lecture, City University of Hong Kong, 2 November 2022
  • The Annual CPS Keynote Lecture at 2018 Joint Annual Conference of Biomedical Science (JACBS), Taipei, 23–25 March 2018
  • The 9th Asian Lecture on Vascular Biology at 8th Scientific Meeting of Asian Society for Vascular Biology, Shanghai, China, 3 November 2018
  • The Robert F. Furchgott Lecture at the 11th International Symposium on Mechanisms of Vasodilatation (MOVD 2013, Zurich, Switzerland, 4 October 2013
  • Invited Institute of Vascular Medicine Keynote Lecture at Annual Scientific Meeting of Institute of Cardiovascular Science and Medicine, Hong Kong, 1 November 2014
  • The Office of Life Sciences Distinguished Lecture at National University of Singapore, 26 April 2007

  • Fudan University Shanghai Medical College (2005)
  • Xi’an Jiaotong University Medical Centre (2005)
  • Center of Medical Sciences, Guangdong Provincial People’s Hospital (2006)
  • Shanghai Jiaotong University Medical College (2007)
  • Jinan University (2008)
  • Peking University, School of Basic Medical Sciences (2010)
  • Third Military Medical University (2010)
  • Beijing Institute of Heart, Lung and Blood Vessel Diseases (2017)
  • University of Science and Technology of China (2023)
  • Member of Scientific Committee, Shanghai City Vascular Biology Key Laboratory (2007)
  • Member of Academic Committee, Shanghai City Key Laboratory of Hypertension (2014)
  • Member of Academic Committee, Center for Obesity and Metabolic Disease at Peking University, China (2010)
  • Member of Academic Committee of Advanced Institute of Medical Sciences, Dalian Medical University (2015)
  • Member of Academic Committee for Shenzhen Key Laboratory of Metabolism and Cardiovascular Homeostasis

  • External Assessor of The Chang Jiang Scholars Program, The Ministry of Education and Li Ka Shing Foundation, China (教育部長(zhǎng)江學(xué)者講座教授, 特聘教授,成就獎(jiǎng)評(píng)審專家)
  • 中央組織部人才工作局青年拔尖人才支援計(jì)畫評(píng)審專家
  • 中國(guó)青年千人計(jì)劃通信評(píng)審專家?guī)鞂<?/li>
  • 中國(guó)國(guó)家科技獎(jiǎng)勵(lì)評(píng)審專家 (2015年度國(guó)家自然科學(xué)獎(jiǎng)會(huì)評(píng)專家,生物學(xué)組)
  • 家自然科學(xué)基金委員會(huì)醫(yī)學(xué)科學(xué)部科學(xué)國(guó)家傑出青年基金
  • 國(guó)家自然科學(xué)基金委員會(huì)醫(yī)學(xué)科學(xué)部科學(xué)國(guó)家優(yōu)秀青年基金
  • External member of the University Assessment Panel for the “UM Macao Talent Program澳大濠江人才計(jì)劃 (UMMTP)” on “UM Macao Post-doctoral Fellowship” and the “UM Macao Distinguished Visiting Scholar”
  • Regular reviewer of manuscripts for 255 international journals and of abstracts for 13 international conferences
  • Regular reviewer of grant proposals for 36 granting agencies and schemes of 15 countries and regions
  • 452 invited lectures and seminars at international, regional and local conferences on vascular research

2024

  • Ding H, Jiang M, Chan AM, Xia Y, Ma RCW, Yao X, Wang L, *Huang Y (2024) Targeting endothelial Src attenuates disturbed flow-induced inflammation and atherogenesis. British Journal of Pharmacology (Accepted)
  • He C, Zhu R, He L, Chook CYB, Li H, Leung FP, Tse G, Chen ZY, *Huang Y, *Wong WT (2024) Asperuloside as a Novel NRF2 Activator to Ameliorate Endothelial Dysfunction in High Fat Diet-Induced Obese Mice. Antioxidants & Redox Signaling (Accepted)
  • Cheng CK, Gao J, Kang LJ, *Huang Y (2024) Fecal microbiota transfer from young mice reverts vascular aging hallmarks and metabolic impairments in aged mice. Aging and Disease 2024 Jul 9. doi:10.14336/AD.2024.0384. Online ahead of print.
  • Zhao Y, Wang L, Huang Y, Evans PC, Little PJ, Tian X, Weng J, Xu S (2024) Anthocyanins in vascular health and disease: mechanisms of action and therapeutic potential. Journal of Cardiovascular Pharmacology June 25, 2024. doi: 10.1097/FJC.0000000000001602
  • Xu MY, Xu JJ, Kang LJ, Liu ZH, Su MM, Zhao WQ, Wang ZH, Lu S, Xiao JB, Evans PC, Tain XY, Wang L, Huang Y, Liang XM, Weng JP, Xu SW (2024) Urolithin A promotes atherosclerotic plaque stability by limiting inflammation and hypercholesteremia in Apolipop rotein E-deficient mice. Acta Pharmacologica Sinica2024 Jun 17. doi: 10.1038/s41401-024-01317-5. Online ahead of print.
  • Liang X, Wang Z, Cai H, Zeng YQ, Chen J, Wei X, Dong G, Huang Y, Lao XQ (2024) Outdoor light at night and mortality in the UK Biobank: a prospective cohort study. Occupational and Environmental Medicine 2023 Nov 22:oemed-2023-109036. doi: 10.1136/oemed-2023-109036. Online ahead of print
  • He L, Chen QH, Wang L, Pu YJ, Huang J, Cheng CK, Luo JY, Kang LJ, Lin X, Xiang L, Fang L, He B, Xia Y, Lui KO, Pan Y, Liu J, Zhang CL, *Huang Y (2024) Activation of Nrf2 inhibits atherosclerosis in ApoE-/- mice through suppressing endothelial cell inflammation and lipid peroxidation. Redox Biology 74:103229. doi: 10.1016/j.redox.2024.103229
  • Chen Q, Hao H, Guo Z, Zuo Y, Cheng CK, Zhang CL, Wang L, Lu A, *Huang Y, He L (2024) Pien Tze Huang (PZH) Protects Endothelial Function in Diabetic Mice. Life Sciences 349:122723. doi;10.1016/j.Ifs.2024.122723
  • Li X, Luo W, Tang Y, Wu J, Zhang J, Chen S, Zhou L, Tao Y, Tang Y, Wang F, Huang Y, Jose PA, Guo L, Zeng C (2024) Semaglutide Attenuates Doxorubicin-Induced Cardiotoxicity through Improving Bnip3-Mediated Mitochondrial Dysfunction. Redox Biology 72(2024):103129. doi: 10.1016/j.redox.2024. 103129.
  • Maxwell S, Okabe J, Kaipananickal H, Rodriguez H, Khurana I, Al-Hasani K, Chow BSM, Pitsillou E, Karagiannis TC, Jandeleit-Dahm K, Ma RCW, Huang Y, Chan JCN, Cooper ME, El-Osta A (2024) Set7 Methyltransferase and Phenotypic Switch in Diabetic Glomerular Endothelial Cells. Journal of the American Society of Nephrology 35(6):733-748. doi: 10.1681/ASN.0000000000000345.. With Commentary, Doke, Tomohito; Bjornstad, Petter, Journal of the American Society of Nephrology 35(6):p 670-672
  • Xiang L, Wang L, Xia Y, Wang Y, Shui J, Zhang CL, Xie L, Ru Y, Cheng CK, Pu Y, Hu L, Liu J, Xu S, Cai ZW, *Huang Y (2024) Exercise Alleviates Diabetic Kidney Disease Through PPARd-CPT1a pathway-dependent Fatty Acid β-oxidation. The Innovation Life 2(2):100065 (10 pages)
  • Liu Y, Wang Y, Xu C, Zhang Y, Wang Y, Qin J, Lan HY, Wang L, Huang Y, Mak K, Zheng Z, Xia Y (2024) Activation of the YAP/KLF5 transcriptional cascade in renal tubular cells aggravates kidney injury. Molecular Therapy 32(5):1526-1539. doi: 10.1016/j.ymthe.2024.02.031.
  • Jin Q, Lau ESH, Luk AO, Tam CHT, Ozaki R, Lim CKP, Wu H, Chow EYK, Kong APS, Lee HM, Fan B, Ng ACW, Jiang G, Lee KF, Siu SC, Hui G, Tsang CC, Lau KP, Leung JY, Tsang MW, Cheung EYN, Kam G, Lau IT, Li JK, Yeung VT, Lau E, Lo S, Fung S, Cheng YL, Chow CC, Yu W, Tsui SKW, Tomlinson B, Huang Y, Lan H, Szeto CC, So WY, Jenkins AJ, Fung E, Muilwijk M, Blom MT, Leen M. ‘t Hart, Chan JCN, Ma RCW on behalf of the Hong Kong Diabetes Biobank Study Group (2024) Circulating metabolomic markers linking diabetic kidney disease and incident cardiovascular disease in type 2 diabetes: association and mediation analyses from the Hong Kong Diabetes Biobank. Diabetologia 67(5):837-849. doi: 10.1007/s00125-024-06108-5.
  • Bo Y, Lin C, Guo C, Wong M, Huang B, Lau A, Huang Y, Lao XQ (2024) Chronic exposure to ambient air pollution and the risk of non-alcoholic fatty liver disease: A cross-sectional study in Taiwan and Hong Kong. Ecotoxicology and Environmental Safety 275:116245.doi: 10.1016/j.ecoenv.2024.116245.
  • Ye P, Deng Y, Gu Y, Liu P, Luo J, Pu J, Chen J , Huang Y, Wang N , Ji Y, Chen S (2024) GRK2–YAP signaling is implicated in pulmonary arterial hypertension development. Chinese Medical Journal (Engl) 137(7):846-858. doi: 10.1097/CM9.0000000000002946.
  • Yuan W, Lin H, Sun Y, Liu L, Yan M, Song Y, Zhang X, Lu X, Xu Y, He Q, Ouyang K, Zhang C, Pan Y, Huang Y, Li Y, Lu X, Liu J (2024) Myocardin reverses insulin resistance and ameliorates cardiomyopathy by increasing IRS-1 expression in a murine model of lipodystrophy caused by adipose deficiency of vacuolar H+-ATPase V0d1 subunit. Theranostics 14(5):2246-2264. doi: 10.7150/thno.93192.
  • Huang YH, Wang YF, Ruan XZ, Lau CW, Wang L, *Huang Y (2024) The Role of KLF2 in Regulating Hepatic Lipogenesis and Blood Cholesterol Homeostasis via the SCAP/SREBP Pathway. Journal of Lipid Research 65(1):100472.doi: 10.1016/j.jlr.2023.100472

2023

  • Jiang M, Ding H, Huang Y, Cheng CK, Lau CW, Xia Y, Yao X, Wang L, *Huang Y (2023) Thioridazine protects against disturbed flow-induced atherosclerosis by inhibiting RhoA/YAP-mediated endothelial inflammation. Acta Pharmacologica Sinica 44(10):1977-1988.
  • Pu Y, Cheng CK, Zhang H, Luo J, Wang L, Tomlinson T, *Huang Y (2023) Molecular mechanisms and therapeutic perspectives of peroxisome proliferator-activated receptor α agonists in cardiovascular health and diseases. Medicinal Research Reviews 43(6):2086-2114.
  • Cheng CK, *Huang Y (2023) Oral microbiome: a doubtful predictor but potential target of cardiovascular diseases. Medical Review 3(3):209-213.
  • Kang L, Yi J, Lau CW, He L, Chen Q, Xu S, Li J, Xia Y, Zhang Y, Huang Y, Wang L (2023) AMPK-dependent YAP inhibition mediates the protective effect of metformin against obesity-associated endothelial dysfunction and inflammation. Antioxidants 2023,12(9):1681 (16 pages)
  • Luo JY, Cheng CK, Gou L, He L, Zhao L, Zhang Y, Wang L, Lau CW, Chen AF, *Huang Y (2023) Induction of KLF2 by exercise activates eNOS to improve vasodilatation in diabetic mice. Diabetes 72(9):1330-1342
  • Cheng CK, Ding H, Jiang M, Yin H, Gollasch M, *Huang Y (2023) Perivascular adipose tissue: Fine-tuner of vascular redox status and inflammation. Redox Biology 62:102683
  • Tam CHT, Lim CKP, Luk AOY, Shi M, Cheung HM, Ng ACW, Lee HM, Lau ESH, Fan B, Jiang G, Kong APS, Ozaki R, Chow EYK, Lee KF, Siu SC, Hui G, Tsang CC, Lau KP, Leung JYY, Cheung EYN, Tsang MW, Kam G, Lau IT, Li JKY, Yeung VTF, Lau E, Lo S, Fung S, Cheng YL, Chow CC, The Hong Kong Diabetes Biobank Study Group, FIELD Study investigators, Fan X, Chan TF, Yip KYL, Lok S, Yu W, Tsui SKW, Lan HY, Szeto CC, Tang NLS, Tomlinson B, Huang Y, Jenkins AJ, Keech A, So WY, Chan JCN, Ma RCW, for the TRANSCEND Consortium (2023) Identification of a common variant for coronary heart disease at PDE1A contributes to individualized treatment goals and risk stratification of for cardiovascular complications in Chinese patients with type 2 diabetes. Diabetes Care 46(6):1271-1281.
  • Ding H, Jiang M, Lau CW, Luo J, Chan AM, Wang L, *Huang Y (2023) Curaxin CBL0137 inhibits endothelial inflammation and atherogenesis via suppression of Src-YAP signaling axis. British Journal of Pharmacology 180(8):1168-1185.
  • Hou C, Cao C, Ma R, Ai L, Hu Z, Huang Y, Yao X (2023) Press-N-Go On-Skin Sensor with High Interfacial Toughness for Continuous Healthcare Monitoring ACS Applied Materials & Interfaces 15(8):11379-11387
  • Wang C, Wu Y, Li Y, Zhang Y, Fung YK, Tong KK, Lau CW, Xiang L, Kwan KM, You LR, *Huang Y, *Tian XY (2023) Smad4-mediated angiogenesis facilitates beiging of white adipose tissue in mice. iScience 26(3):106272 (17 pages)
  • Zhang Y, Huang H, Kong Y, Xu C, Dai L, Geng X, Deng Y, Wang Y, Liu Y, Meng C, Zhang X, Li J, Qin J, Feng B, Mak KK, Wang L, Huang Y, Wang W, Lan HY, Yang B, Lu HAJ, Xia Y (2023) Kidney tubular transcription co-activator, Yes-associated protein 1 (YAP), controls the expression of collecting duct aquaporins and water homeostasis. Kidney International 103(3):501-513
  • Bei Y, Chen C, Hua X, Yin M, Meng X, Huang Z, Liu C, Lehmann HI, Li G, Huang Y, Xiao J (2023) A modified apical resection model with high accuracy and reproducibility in neonatal mouse and rat hearts. npj Regenerative Medicine 8(1):9, 13 pages
  • Khurana I, Harikrishnan KN, Maxwell S, Birkelund S, Syreeni A, Forsblom C, Okabe J, Ziemann M, Kaspi A, Rafehi H, J?rgensen A, Al-Hasani K, Thomas MC, Jiang G, Luk AOY, Lee HM, Huang Y, Thewjitcharoen Y, Nakasatien S, Himathongkam T, Fogarty C, Njeim R, Eid A, Hansen TW, Tofte N, Ottesen EC, Ma RCW, Chan JCN, Cooper ME, Rossing P, Groop P, El-Osta A (2023) Reduced methylation corresponds with T1D nephropathy risk, Journal of Clinical Investigator 133(4):e160959
  • Chen H, Peng J, Wang T, Wen J, Chen S, *Huang Y, Zhang Y (2023) Counter-regulatory renin-angiotensin system in hypertension: review and update in the era of COVID-19 pandemic. Biochemical Pharmacology 208 (2023):115370
  • Xiang L, Ru Y, Shi J, Wang L, Zhao H, *Huang Y, Cai Z (2023) Derivatization of N-Acyl Glycines by 3-Nitrophenylhydrazine for Targeted Metabolomics Analysis and Their Application to the Study of Diabetes Progression in Mice. Analytical Chemistry 95(4):2183-2191.
  • Cheng CK, Lin X, Pu Y, Tse KYJ, Wang Y, Zhang CL, Cao X, Lau CW, Huang J, He L, Luo JY, Shih YT, Wan S, Ng CF, Wang L, Ma CWR, JJ Chiu, Chan TF, Tian XY & *Huang Y (2023) SOX4 is a novel phenotypic regulator of endothelial cells in atherosclerosis revealed by single-cell analysis. Journal of Advanced Research 43:187-203.

2022

  • Jin Q, Lau ESH, Luk AO, Tam CHT, Ozaki R, Lim CKP, Wu H, Chow EYK, Kong APS, Lee HM, Fan B, Ng ACW, Jiang G, Lee KF, Siu SC, Hui G, Tsang CC, Lau KP, Leung JY, Tsang MW, Cheung EYN, Kam G, Lau IT, Li JK, Yeung VT, Lau E, Lo S, Fung S, Cheng YL, Chow CC, Yu W, Tsui SKW, Huang Y, Lan HY, Szeto CC, So WY, Jenkins AJ, Chan JCN, Ma RCW (2022) High-density lipoprotein subclasses and cardiovascular disease and mortality in type 2 diabetes: analysis from the Hong Kong Diabetes Biobank. Cardiovascular Diabetology 21(1):293.
  • Lui KO, Huang Y (2022) Prohibitin 2 governs glucose metabolism and phenotypic switching of vascular smooth muscle cells during vascular remodeling. Circulation Research (Editorial) 131(10):825-827
  • Jiang M, Ding H, *Huang Y & Wang L (2022) Shear Stress and Metabolic Disorders-Two Sides of the Same Plaque. Antioxidants & Redox Signaling 37(10-12): 820-841.
  • Huo M, Cao X, Zhang H, Lau CW, Hong H, Chen FM, Huang Y, Chawla A & Tian XY (2022) Loss of Myeloid Bmal1 Exacerbates Hypertensive Vascular Remodelling Through Interaction with STAT6 in Mice. Cardiovascular Research 118(13):2859-2874.
  • Luo JY, Cheng CK, He L, Pu Y, Zhang Y, Lin X, Xu A, Lau CW, Tian XY, Ma RCW, Jo H & *Huang Y (2022) Endothelial UCP2 is a mechanosensitive suppressor of atherosclerosis. Circulation Research 131(5):424-441.
  • Wan Q, Xu C, Zhu L, Zhang Y, Peng Z, Chen H, Zhang E, Wu Y, Wang H, Chu F, Yuan J, Huang Y, Hu S, Liu DP, Wang M (2022) Targeting PDE4B (phosphodiesterase-4 subtype B) for cardioprotection in acute myocardial infarction via neutrophils and microcirculation. Circulation Research 131(5):442-455.
  • Zhang H, Dong J, Lau CW, Wei Y & *Huang Y (2022) Berberine reverses nitroglycerin tolerance through suppressing PKCa activity in vascular smooth muscle cells. Cardiovascular Drugs and Therapy 36(4):633-643
  • Zhang Y, Wang Y, Zheng G, Liu Y, Li J, Huang H, Xu C, Zeng Y, Zhang X, Qin J, Dai C, Hambrock HO, Hartmann U, Feng B, Mak KK, Liu Y, Lan HY, Huang Y, Zheng ZH Xia Y (2022) Follistatin-like 1 (FSTL1) interacts with Wnt ligands and Frizzled receptors to enhance Wnt/β-catenin signaling in obstructed kidneys in vivo. Journal of Biological Chemistry 298(7):102010
  • He L, Zhang CL, Chen QH, Wang L & *Huang Y (2022) Endothelial shear stress signal transduction and atherosclerosis: From mechanisms to therapeutics. Pharmacology & Therapeutics 235; (2022) 108152
  • Zhang H, Xiang L, Huo M, Wu Y, Yu M, Lau CW, Tian D, Gou L, Huang Y, Luo JY, Wang L, Song W, Huang J, Cai Z, Chen S, Tian XY & *Huang Y (2022) Branched-chain amino acid supplementation Impairs Insulin Sensitivity and Promotes Lipogenesis During Exercise in Diet-Induced Obese Mice. Obesity (Silver Spring). 30(6):1205-1218.
  • Cheng CK, Shang W, Liu J, Cheang WS, Wang Y, Xiang L, Lau CW, Luo JY, Ng CF, *Huang Y, *Wang L (2022) Activation of AMPK/miR-181b Axis Alleviates Endothelial Dysfunction and Vascular Inflammation in Diabetic Mice. Antioxidants 11(6):1137 (17 pages)
  • Zhang H, Peng L, Wang Y, Zhao W, Lau WB, Wang Y, Li Y, Du Y, Li L, Huang Y, Nie S, Qin Y, Ma X, Wei Y (2022) Extracellular vesicle-derived miR-144 as a novel mechanism for chronic intermittent hypoxia-induced endothelial dysfunction. Theranostics 12(9): 4237-4249. doi:10.7150/thno.69035
  • Lifang Han; Gang Wang; Shaopu Zhou; Chenghao Situ; Zhiming He; Yuying Li; Yu Huang; Aimin Xu; Michael Tim Yun Ong; Huating Wang; Jianfa Zhang; Zhenguo Wu (2022) Muscle Satellite Cells are impaired in Type 2 Diabetic Mice by Elevated Extracellular Adenosine. Cell Reports 39(10):110884.
  • Zhang C, He L, Wang L & *Huang Y (2022) The pathogenesis of endothelial dysfunction (內(nèi)皮功能障礙的發(fā)生機(jī)制) SCIENTIA SINICA Vitae (中國(guó)科學(xué):生命科學(xué)) 52(5):691-698.
  • Zhao L, Zhang CL, He L, Chen QH, Liu L, Kang L, Liu J, Luo JY, Gou L, Qu D, Song W, Lau CW, Ko H, Mok VCT, Tian XY, Wang L & *Huang Y (2022) Restoration of Autophagic Flux Improves Endothelial Function in Diabetes Through Reducing Mitochondrial ROS-mediated eNOS Monomerization. Diabetes 71(5):1099-1114. doi: 10.2337/db21-0660
  • Wang L, Cheng CK, Yi M, Lui KO, *Huang Y (2022) Targeting endothelial dysfunction and inflammation. Journal of Molecular and Cellular Cardiology 168:58-67.
  • Ma Z, Li X, Fan RLY, Yang KY, Ng CSH, Lau RWH, Wong RHL, Ng KK, Wang CC, Ye P, Fu Z, Chin AWH, Lai MYA, Huang Y, Tian XY, Poon LLM, Lui KO (2022) A human pluripotent stem cell-based model of SARS-CoV-2 infection reveals an ACE2-independent inflammatory activation of vascular endothelial cells through TLR4. Stem Cell Reports 17(3):538-555.
  • Ma Z, Yang K, Huang Y & Lui KO (2022) Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications. Journal of Molecular and Cellular Cardiology 164:69-82
  • Jiang G, Luk AO, Tam CHT, Ozaki R, Lim CKP, Chow EYK, Lau ES, Kong APS, Fan B; Hong Kong Diabetes Register TRS Study Group, Lee KF, Siu SC, Hui G, Tsang CC, Lau KP, Leung JY, Tsang MW, Kam G, Lau IT, Li JK, Yeung VT, Lau E, Lo S, Fung S, Cheng YL, Chow CC; Hong Kong Diabetes Biobank Study Group, Tang NL, Huang Y, Lan HY, Oram RA, Szeto CC, So WY, Chan JCN, Ma RCW (2022)Clinical Predictors and Long-term Impact of Acute Kidney Injury on Progression of Diabetic Kidney Disease in Chinese Patients with Type 2 Diabetes. Diabetes. 71(3):520-529.
  • Cui Y, Kassmann M, Nickel S, Zhang C, Alenina N, Anistan YM, Schleifenbaum J, Bader M, Welsh DG, Huang Y & Gollasch M (2022) Myogenic vasoconstriction requires canonical Gq/11 signaling of the angiotensin II type 1 receptor. Journal of American Heart Association1 1(4);e022070 (14 pages),
  • Zhong W, Cao X, Pan G, Niu Q, Feng X, Xu M, Li M, Huang Y, Yi Q & Yan D (2022) ORP4L is a prerequisite for the induction of T-cell leukemogenesis associated with human T-cell leukemia virus 1. Blood 139(7):1052-1065.
  • Wu Y, Tang X, Lee S, Hong H, Cao X, Lau CW, Liu B, Chawla A, Ma RCW, Huang Y, Lui KO, Tian XY (2022).Endothelial PPARδ facilitates the post-ischemic vascular repair through interaction with HIF1α. Theranostics 12(4):1855-1869.
  • Teoh YCJ, Tian XY, Wong YPC, Lau CW, Cheng CK, Tang WLV, Chan CKR, Huang Y & Ng CF (2022) Endothelial dysfunction after androgen deprivation therapy and the possible underlying mechanisms. Prostate 82(1):13-25.

16 September 2024

More Faculty
皇城百家乐娱乐城| 永利博娱乐| 六合彩网页| 新2娱乐城| 百家乐官网机器手怎么做弊| 破解百家乐官网视频游戏密码| 怎么玩百家乐能赢钱| 新澳博天上人间娱乐| 澳门百家乐下三路| 巴彦县| 海立方百家乐客户端| 定远县| 金鼎百家乐局部算牌法| 百家乐官网机械投注法| 百家乐对冲套红利| 百家乐官网破解之法| 澳门百家乐官网博| 大发888最新网址| 澳门百家乐官网打法百家乐官网破解方法 | 老虎机遥控器| 七乐百家乐现金网| 大发888通宝| 法拉利百家乐官网的玩法技巧和规则 | 百家乐官网必胜下注法| 百家乐投注程式| 菲律宾百家乐官网娱乐网| 百家乐赌场公司| 甘洛县| 百家乐投注注技巧| 庐江县| 大发888娱乐场下载 17| 欢乐博百家乐官网娱乐城| 大发888官方下载网址| 至尊百家乐2012| 百家乐官网投注方法投资法| 大发888 大发888官网| 百家乐破解| 澳门百家乐官网网址多少| 大发888娱乐场大发888娱乐场下载| 澳门百家乐怎玩| 百家乐官网冼牌机|